Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Zevra Therapeutics, Inc. (ZVRA) had Revenue of $34.12M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$34.12M
Net Income	$13.32M
Cost of Goods Sold	$1.52M
Gross Profit	$32.60M
Operating Expenses	$24.81M
Operating Income	$9.31M
Non-Operating Income/Expense	$3.35M
Pre-Tax Income	$12.67M
Normalized Pre-Tax Income	$12.67M
Income after Taxes	$12.16M
Income from Continuous Operations	$12.16M
Consolidated Net Income/Loss	$12.16M
Normalized Income after Taxes	$12.16M
EBIT	$9.31M
EBITDA	$8.82M
Weighted-Average Shares Outstanding (Basic)	55.31M
Weighted-Average Shares Outstanding (Diluted)	57.26M
Earnings per Share (EPS) (Basic)	$0.23
Earnings per Share (EPS) (Diluted)	$0.21
Balance Sheet Financials
Current Assets	$223.01M
Property, Plant, and Equipment	$0.49M
Long-Term Assets	$61.72M
Total Assets	$284.73M
Current Liabilities	$39.28M
Long-Term Debt	$61.93M
Long-Term Liabilities	$90.80M
Total Liabilities	$130.07M
Common Equity	$154.66M
Tangible Shareholders Equity	$143.53M
Shareholders Equity	$154.66M
Common Shares Outstanding	56.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-1.60M
Cash Flow from Investing Activities	$18.13M
Cash Flow from Financial Activities	$12.06M
Beginning Cash	$33.78M
End Cash	$62.41M
Increase/Decrease in Cash	$28.62M
Stock-Based Compensation	$12.71M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.68
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.29
Debt to Equity Ratio	0.40
Gross Margin	95.55%
Operating Margin	27.30%
EBIT Margin	27.30%
EBITDA Margin	--
Pre-Tax Profit Margin	37.12%
Profit Margin	39.03%
Free Cash Flow	$-1.99M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.87
Receiveable Turnover	1.47
Days Sales in Receivables	61.34
Return on Equity	7.87%
Return on Tangible Equity	8.48%
Return on Assets	4.27%
Return on Investments	5.62%
Book Value Per Share	$2.72
Free Cash Flow per Share	$-0.03
Operating Cash Flow per Share	$-0.03

Data from Zacks Investment Research, Inc.